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Abstract
Background: Squamous Cell Carcinoma of Esophagus is one of the most common malignancies in both men and
women in eastern and south-eastern Africa. In Kenya, clinical observations suggest that this cancer is frequent in
the Rift Valley area. However, so far, there has been no report on the molecular characteristics of esophageal
squamous cell carcinoma (ESCC) in this area.
Results: We have analyzed TP53 mutations, the presence of human papilloma virus (HPV) DNA and expression of
inflammation markers Cyclooxygenase 2 (Cox-2) and Nitrotyrosine (NTyR) in 28 cases (13 males and 15 females) of
archived ESCC tissues collected at the Moi Teaching and Referral Hospital in Eldoret, Kenya. Eleven mutations were
detected in TP53 exons 5 to 8 (39%). All ESCC samples were negative for HPV 16, 18, 26, 31, 33, 35, 39, 45, 51, 52,
53, 56, 58, 59, 66, 68, 70, 73 and 82. Immunohistochemical analysis of Cox-2 and NTyR showed a low proportion of
positive cases (17.4% and 39.1%, respectively). No association between the above markers and suspected risk
factors (alcohol or tobacco use, hot tea drinking, use of charcoal for cooking) was found.
Conclusion: Our findings suggest that mechanisms of esophageal carcinogenesis in eastern Africa might be
different from other parts of the world. Low prevalence of TP53 mutation compared with other intermediate or
high incidence areas of the world highlights this hypothesis. Our data did not support a possible ole of HPV in this
series of cases. Further studies are needed to assess and compare the molecular patterns of ESCC from Kenya with
those of high-incidence areas such as China or Central Asia.
Background
Esophageal Squamous Cell Carcinoma (ESCC) is the 6
th
most common cancer worldwide. About 80% of the
cases occur in low and middle income countries, with
large geographic variations in incidence [1]. The highest
rates (over 50 per 100.000 person-years) are observed in
areas of central Asia (in particular Northern Iran and
central China). Intermediate incidence rates have been
reported for parts of Latin America (Southern Brazil,
Uruguay) and several regions in Europe (Western
France, Hungary) [2]. The main risk factors in Western
Countries include, combined consumption of tobacco
and alcohol. In high incidence areas, a number of differ-
ent factors such as hot tea consumption, low socio-eco-
nomic status, low fresh fruit and vegetable intake and
exposure to dietary carcinogens have been suggested to
play a role [3-8]. The involvement of chronic infection
by human papilloma viruses (HPV) is a controversial
issue. Early results showing a high prevalence of HPV
DNA in cases from high incidence areas of China [9,10]
have not been confirmed in more stringent, recent
studies [11,12].
ESCC has consistently been reported to be a frequent
cancer in both males and females in southern and east-
ern Africa. In South Africa (Transkei region), molecular
studies have reported a low prevalence of mutations in
* Correspondence: abedib@iarc.fr
4Digestive Disease Research Institute, Shariati Hospital, Tehran University of
Medical Sciences, Tehran, Iran
Full list of author information is available at the end of the article
Patel et al. BMC Research Notes 2011, 4:469
http://www.biomedcentral.com/1756-0500/4/469
© 2011 Abedi-Ardekani et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.e x o n s5t o8o ft h eTP53 tumor suppressor gene (17%)
[13-16], well below the world average (40%) and the
high prevalence observed in high incidence areas of
China (70%) [17,18] or Northern Iran (90%) (Abedi-
Ardekani et al, not published). So far, there is no data
on TP53 mutation prevalence in ESCC from other parts
of Africa.
ESCC is a common cancer in some rural areas of
Kenya [19]. In the Rift Valley, ESCC is the leading
malignancy in males and the third after cervical and
breast cancers in females [20,21]. A recent study in the
B o m e tD i s t r i c t ,W e s t e r nK e n y a ,s h o w e dt h a tE S C C
accounted for 914 (34.6%) of the 2643 cancers diag-
nosed between January 1999 and December 2007, with
6.3% of the patients less than 31 years [22].
We have performed a pilot study on 28 archived, paraf-
fin embedded ESCC tissues from patients referring to the
Moi Teaching and Referral Hospital (MTRH, Eldoret,
K e n y a ) .W eh a v ea n a l y s e dTP53 mutations in exons 5 to
8, presence of high risk types of HPV, and Immunohisto-
chemical (IHC) expression of two markers associated
with inflammation damage (NTyR, a direct marker of
protein damage by nitric oxide over expressed in ESCC
linked with inflammation, [23,24] and inflammatory
response (Cox-2, which is often elevated in ESCC from
various high-incidence areas, [25]).
Methods
Patient selection
Patients who underwent resection for primary ESCC at
MTRH, Eldoret, Kenya, between June 2003 and July 2006
were recruited into the study. Diagnosis was performed
at the histopathology department, MTRH, and confirmed
at the International Agency for Research on Cancer
(IARC). A group of 37 properly fixed and processed
ESCC samples was assembled for further molecular stu-
dies. The patients were part of a case-control study with
information on risk factors obtained through question-
naires at the time of diagnosis. All patients involved in
that study had signed a written consent. (Patel K. et al.,
unpublished, manuscript in preparation). The study was
approved by Ethics Review board of MTRH and of IARC.
DNA extraction, TP53 mutation and HPV analysis
DNA was extracted from areas of tissue sections contain-
ing over 50% of cancer cells as identified by a pathologist
at IARC (B.A-A) using a column-based purification
method. A total of 28 samples provided enough DNA of
suitable quality for molecular analyses. TP53 mutations in
exons 5-8 were analyzed using the IARC reference proto-
col http://www-p53.iarc.fr/Download/TP53_DirectSequen-
cing_IARC.pdf. Samples were analysed by bidirectional
sequencing and the analysis was repeated with two inde-
pendent PCR products. Sequencing results were compared
with the reference sequence X54156 from Genbank http://
p53.iarc.fr/TP53sequenceX54156.html. Sequence varia-
tions were checked with the mutation validation tool of
the IARC TP53 mutation database http://www-p53.iarc.fr/
MutationValidationCriteria.asp.
HPV typing was performed as previously described
[26]. Briefly, detection and typing of 19 mucosal high-risk
HPV types (types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53,
56, 58, 59, 66, 68, 70, 73, and 82) was performed by a
combination of multiplex PCR and HPV type-specific
primers for amplification of viral DNA (E7). PCR pro-
ducts were typed using arrayed primer extension (APEX).
Amplification of Beta-globin was used as positive reac-
tion control.
Immunohistochemistry
Among 28 cases, IHC study was possible on 23. Depar-
affinised sections (5 μM) were rehydrated and incubated
with primary antibodies for either one hour at room
temperature (DO7, mouse-anti p53 monoclonal anti-
body 1:500, Dako, Glostrup, Denmark), or overnight at
4°C (COX-2, polygoat, 1/2000, Santa Cruz Biotechnol-
ogy) and NTyR (polyrabbit 1/2000, Upstate Biotechnol-
ogy). Fixed antibodies were detected with secondary
biotinylated anti-rabbit IgG (1/200, Vectasin Elite-ABC
kit, Vector Laboratories Inc.) followed by streptavidin-
peroxidase and diaminobenzidine-based detection
according to standard protocols (Vector Laboratories,
Inc.) A score combining intensity of staining (0 to 3)
and proportion of stained cancer cells (0-10%: 0; 11-
30%: 1; 31-50%: 2; over 50%: 3) was used. The combined
scores ranging from 0-9 were scored into 3 final groups:
0-3 (no to weak expression), 4-6 (moderate expression),
and 7-9 (strong expression).
Results
The characteristics of the 28 patients analyzed for both
TP53 mutations and HPV DNA are summarized in
Table 1. This group comprised an approximately equal
proportion of males and females, in agreement with the
known gender distribution of ESCC in the population of
t h eR i f tV a l l e y[ 2 1 ] .A g ea td i a g n o s i sr a n g e df r o m2 3t o
72 years (average of 56 years) with no difference
between genders. All cases were invasive carcinoma.
Among possible risk factors, tobacco was predomi-
nantly used as smoked product in males and as snuff in
females. Alcohol drinking showed a strong bias towards
men (9 males for 1 female). Exposure to charcoal fumes
was almost restricted to women (11 of 12 exposed
patients were women). Other factors, such as hot tea
drinking, consumption of mursik (a local fermented milk
product laced with charcoal) and poor oral hygiene (as
documented by tooth loss) were equally distributed
between genders.
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Page 2 of 6TP53 mutations (Table 2) were detected in 11 of 28
patients (39.3%). None of these mutations occurred at
common TP53 mutation hotspots as reported in the
IARC TP53 database. Of the mutations, 6 were missense,
3 nonsense and 2 were deletions inducing frameshift and
supposed to lead to premature termination of translation.
Only one mutation was a transversion (A:T to T:A at
codon 255, p.I255F). Among transition mutations, 3 were
at CpG sites, all leading to nonsense substitutions.
Typing of 19 mucosal high-risk HPV types in the
same DNA extracts as those used for TP53 mutation
detection gave negative results (data not shown).
Immunohistochemical analysis on 23 cases (Figure 1 and
Table 3) showed p53 protein accumulation (final groups of
moderate and strong expression) in 18 (78.2%) of the
cases. Among 11 cases with TP53 mutations, IHC analysis
was possible on 6 and 5 had moderate or strong p53
expression scores. NTyR and Cox-2 were absent or weakly
expressed in, respectively, 14 (60.9%) and 19 (82.6%) of the
cases, suggesting that expression of markers of inflamma-
tion was not a common characteristic of these ESCC cases.
Discussion
This study is the first report on the molecular character-
istics of ESCC from patients of the Rift Valley, a possibly
high incidence area in Eastern Africa. Although limited
to 28 cases, this series is of interest since there is no
report for ESCC in Africa except for a study in Transkei,
South Africa [27]. In the present series, men and women
were equally represented, a gender distribution similar to
most high incidence areas where tobacco and alcohol are
not the main risk factors for ESCC, such as in Northern
Iran or in central China [2,7,28]. However, from a mole-
cular viewpoint, ESCC from Rift Valley appears different
from those high incidence areas in the prevalence of
TP53 mutations. We report a prevalence of TP53 muta-
tion of 39%, far below the high prevalence reported in
high incidence areas of China (50-75%) [17,29-32],
Northern Iran (90%) (Abedi-Ardekani et al., not pub-
lished) or Western France (Normandy, 76%) [33].
Remarkably, a low prevalence of TP53 mutations has also
been reported in Transkei [27]. Furthermore, the muta-
tions identified, both in the present study and in Trans-
kei, differ from the average mutation patterns of most
cancers which are dominated by transition mutations at
“hotspot” codons within CpG sites [34]. Although the
small size of this study precludes any detailed analysis of
mutation patterns, these results, together with those pre-
viously published for ESCC from Transkei, suggest that
ESCC in south-eastern Africa may develop in a different
mutagenic context than ESCC in other high-incidence
areas. Of note, mutation analysis was limited to exons 5
to 8 since these exons contain about 90% of know muta-
tions in ESCC and were the only exons previously ana-
lyzed in ESCC from Africa [27]. This choice was made
necessary by the fact that only limited amounts of DNA
was available from these formalin-fixed paraffin tissues.
Table 1 Patient’s characteristics and suspected risk
factors
Patient’s characteristics, n = 28 Number
Gender Males 13
Females 15
Age Average 56.03 ± 12.30
Range 23-72
Tobacco use Smoking (ever; male/female) 6/0
Snuff (ever; male/female) 0/7
Any (ever/never) 13/15
Alcohol use (ever; male/female) 9/1
Hot tea drinking* (yes; male/female) 6/11
Consumption of Mursik (yes; male/female) 8/10
Oral hygiene
+ (poor; male/female) 8/8
Charcoal cooking (yes; male/female) 1/12
*: “hot” was considered as immediate drinking after pouring boiling tea
+: Estimated on the basis of tooth loss
Table 2 Characteristics of mutations in Esophageal Squamous Cell Carcinomas from Kenya
Exon Gene position cDNA position Codon and amino-acid change Mutation Mutation type
5 g.12524A > G c.536A > G p.H179R His-Arg Missense A:T > G:C
6 g.12706C > T c.637C > T p.R213X Arg-Stop Nonsense G:C > A:T at CpG
6 g.12706C > T c.637C > T p.R213X Arg-Stop Nonsense G:C > A:T at CpG
7 g.13386C > T c.749C > T p.P250L Pro-Leu Missense G:C > A:T
7 g.13400A > T c.763A > T p.I255F Ile-Phe Missense A:T > T:A
8 g.13776G > A c.796G > A p.G266R Gly-Arg Missense G:C > A:T
8 g.13813C > T c.833C > T p.P278L Pro-Leu Missense G:C > A:T
8 g.13816G > A c.836G > A p.G279E Gly-Glu Missense G:C > A:T
8 g.13896C > T c.916C > T p.R306X Arg-Stop Nonsense G:C > A:T at CpG
8 g.13811_13815del5 c.831_835del5 p.? FS* -
6 g.12729_12732del4 c.660_663del4 p.? FS -
* FS: Frame Shift
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Page 3 of 6Low prevalence of TP53 mutations suggested that other
molecular events may take place in ESCC from the Rift
Valley. To address this hypothesis, we analyzed the pre-
sence of HPV DNA and the expression of markers of
inflammation. High-risk HPV are known to contribute to
carcinogenesis by inactivating the p53 protein in cervical
and in oral cancers, thus bypassing the need for TP53
mutation [35,36]. Using a highly sensitive assay for high-
50 M
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Figure 1 Detection of Cox-2, N-TyR and p53 proteins by immunohistochemistry in ESCC tissues (×400). Typical examples of negative (left
panels) or positive (right panels) staining are shown. (a-b): Cox-2; (c-d): N-TyR; (e-f): p53. Bar: scale in μm.
Table 3 Expression scores for p53, Cox-2 and NTyR in 23 cases of Esophageal Squamous Cell Carcinomas from Kenya
Expression Score groups p53 No. (%) Cox-2 No. (%) N-Tyrosine No. (%)
Absent or weak (0-3) 5 (21.8) 19 (82.6) 14 (60.9)
Moderate (4-6) 9 (39.1) 3 (13.0) 5 (21.7)
Strong (7-9) 9 (39.1) 1 (4.4) 4 (17.4)
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Page 4 of 6risk HPV, we failed to detect any HPV sequences in the 28
cases tested. These results support the conclusions of a
previous analysis performed on 29 biopsies of ESCC col-
lected in the Bomet District, Western Kenya [37].
With respect to inflammation markers, only a small
proportion of ESCC from the Rift Valley showed posi-
tive staining for either NTyR or Cox-2, two markers
that we reported as highly expressed in ESCC from Iran
(Tehran area) [23]. These results suggest that wide-
spread inflammation is not a characteristic of ESCC in
the Rift Valley. However, data on inflammation status of
normal mucosa are needed to determine whether
i n f l a m m a t o r yc o n d i t i o n sm a yp l a yar o l ei nt h ee a r l y
steps of esophageal carcinogenesis.
Conclusions
The results presented here highlight that mechanisms of
carcinogenesis in ESCC in eastern Africa may differ from
other areas of the world. In particular, the low prevalence
of TP53 mutation, also observed in ESCC from South
Africa, suggests that some other mechanism of p53 inac-
tivation may take place in these cancers. Our data do not
support a role for HPV in this process. Furthermore, the
risk factors associated with ESCC in Africa is poorly
known. In South Africa, fumonisin, a mycotoxin that
contaminates several components of the diet, have been
proposed as significant risk factors [38,39]. Although
fumonisins are present in the diet in east Africa [40], no
study so far has addressed their potential role in the etiol-
ogy of ESCC in the Rift Valley. If further studies with lar-
ger sample size and sequencing of all TP53 exons
confirm our findings, then we may assume that the type
of risk factors and/or mechanisms of carcinogenesis in
ESCC in Eastern Africa are different from other high-
incidence areas of the world.
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